NIH

Molecular characterization of pre-cancerous changes in cells lining the stomach could point to lesions with a greater risk of progression to cancer. Read More

The Vanderbilt Vaccine Research Program has received a major contract from the National Institutes of Health to continue its work as one of the nation’s Vaccine and Treatment Evaluation Units. Read More

Vanderbilt’s Vaccine and Treatment Evaluation Unit (VTEU) is one of nine U.S. sites funded by the National Institute of Allergy and Infectious Disease (NIAID), part of the National Institutes of Health (NIH), to test the effectiveness of a vaccine to protect against the H7N9 bird flu that emerged in China this spring. Read More

Vanderbilt investigators used an in vivo screen in zebrafish to identify a potential new anti-cancer drug. Read More

New mass spectrometry imaging methods will enable studies of the distribution and identification of membrane proteins directly within tissues. Read More

Therapeutic nanoparticles may offer a powerful new way to image and treat cancer at the same time. Read More

Vanderbilt investigators have combined next-generation sequencing technologies and bioinformatics analyses to screen for genome-wide genetic mutations associated with drug resistance in a series of lung cancer cell lines. Read More

A coronavirus protein is required for replication of the viral genome and may be a good treatment target for SARS and other diseases caused by coronaviruses. Read More

A new in vitro system will allow investigators to explore how immune system T cells develop specialized functions. Read More

A newly identified factor regulates blood vessel growth in colorectal tumors and could be a promising target for cancer therapies. Read More